D. E. Shaw & Co., Inc. Aerovate Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.68 - $29.57 $305,245 - $510,526	17,265 New	17,265 $510,000
Q1 2023 May 15, 2023	SELL	$19.17 - $27.7 $259,485 - $374,947	-13,536 Reduced 45.89%	15,958 $321,000
Q4 2022 Feb 14, 2023	SELL	$15.92 - $30.52 $76,431 - $146,526	-4,801 Reduced 14.0%	29,494 $864,000
Q3 2022 Nov 14, 2022	BUY	$14.77 - $25.79 $506,537 - $884,468	34,295 New	34,295 $569,000

28.1M

116K

26.6K

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $63.6M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.